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Abstract
Introduction Synovitis–acne–pustulosis–hyperostosis–
osteitis (SAPHO) is an acronym for various osteoarticular
and dermatological manifestations that can appear in the
same patient. It is a rare syndrome, but since its awareness
has increased, there have been more and more such reports
in the literature.
Aims The objectives of this review are to summarize the
current state of knowledge on pediatric and adult-onset
SAPHO syndrome, and to discuss treatment strategies that
should be considered.
Results The SAPHO syndrome can affect patients of any
age, and its etiology is still not known. The syndrome has
its cognizable radiological characteristics that are most
important in making the diagnosis. There are several
diagnostic criteria as well, but they need further validation.
No standard treatment protocols are available and current
treatment options are not evidenced-based due to the rarity
of the syndrome. Therapy is empirical and aimed at easing
pain and modifying the inflammatory process. It includes
nonsteroidal anti-inflammatory drugs (NSAIDs) as the
first-line agents. Antibiotics, corticosteroids, disease-mod-
ifying anti-rheumatic drugs, biologicals targeting tumor
necrosis factor alpha or interleukin-1, and bisphosphonates
have all been used with variable success. Surgery is
reserved to treat complications. Even though it is a disease
with good long-term prognosis, its treatment remains a
challenge and the results are known to be disappointing,
especially with the skin component of the disease.
Conclusion It is expected that these patients present at the
time of diagnosis and the treatment should be as early,
effective, and safe as possible in order to prevent osteo-
articular progression and to limit the adverse events asso-
ciated with pharmacological drugs.




osteitis) syndrome was first introduced by the rheumatol-
ogist Chamot in 1987, and it is characterized by a combi-
nation of skin and osteoarticular manifestations. The term
attempts to comprise numerous names that have been used
in the literature for the last 50 years, describing the above-
mentioned characteristics. Some of those names are bilat-
eral clavicular osteomyelitis with palmar and plantar pus-
tulosis, inter-sterno-costo-clavicular ossification, subacute
and chronic symmetric osteomyelitis, arthro-osteitis asso-
ciated with a follicular occlusive triad, sternoclavicular
hyperostosis, nonbacterial osteitis, pustulotic arthro-oste-
itis, chronic recurrent multifocal osteomyelitis (CRMO),
Koehler’s disease, pyogenic sterile arthritis, acquired
hyperostosis syndrome, or spondyloarthritis hyperostotica
pustulo-psoriatica [1–4]. CRMO will be discussed more in
detail in this review as well, due to the great confusion that
these two terms generate in the literature. Numerous
authors have suggested that CRMO and SAPHO lie along
the same clinical spectrum. Some believe that CRMO is the
pediatric presentation of SAPHO, even though there are
some rare descriptions of SAPHO seen in children and
seldom in adolescents, as well as descriptions of CRMO in
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adults. It seems that the differentiating clinical feature is
mainly in the localization of inflammation: in pediatric
CRMO, the extremities are more often affected, whereas in
SAPHO, the axial skeleton with costosternoclavicular
region is the focus [5–9].
SAPHO is considered a rare disease and sufficient data
on its prevalence are unavailable. It is predominantly found
in patients with average ages of 30 and 50 years [10].
Hayem et al. [11] reviewed 120 cases of SAPHO and
revealed that there is a female predominance among
patients younger than 30 years old at the beginning of the
disease. Despite all of this, there is a considerable number
of reports on children who suffer from SAPHO, and, today,
it is considered that it can evolve at any age [1]. The
youngest described patient was only 15 months old [12].
According to some authors, the annual prevalence is esti-
mated at 1/10,000 in Caucasians [6, 13] or 0.00144/
100,000 in Japanese [14–16].
The clinical presentation is heterogeneous and patients
may, therefore, present to different specialists. SAPHO is
well known to dermatologists and rheumatologists, but
there are only a few reports in the orthopedic literature.
Since the disease can evolve at any age, it is important to
present such literature to clinicians dealing with children,
especially since various manifestations (pustulosis and
osteitis) do not necessarily coincide. Recognizing the dis-
ease in time will prevent osteoarticular progression.
Otherwise, patients can suffer deformity, loss of function,
and increasing pain, which might require wide resections.
A MEDLINE search using SAPHO, SAPHO syndrome,
and chronic recurrent multifocal osteomyelitis as keywords
was performed and, further, relevant articles from retrieved
references were extracted.
The objectives of this review article are to review the
etiology, presentation, diagnosis, treatment, pathogenesis,
and genetics of the syndrome and to raise awareness of this
entity.
Etiology
Whether the SAPHO syndrome represents a clinical entity
by itself, should be considered a subset within the family of
spondyloarthropathies (due to the frequent affliction of the
axial skeleton, enthesitis, and inflammatory bowel dis-
eases), or be considered a variant of another rheumatic
disease (i.e., psoriatic arthritis) is still unknown [2].
The pathogenesis of SAPHO is probably multifactorial
and it involves a combination of genetic, infectious, and
immunological components.
The published data show that HLA-B27 is more fre-
quent in SAPHO, but spondyloarthropathies overlap with
SAPHO, and statistical analyses performed on those
cohorts resulted in a higher proportion of HLA-B27
SAPHO patients. Therefore, it is no wonder that other
studies refute these data and showed that there are no
relations between SAPHO and HLA-B27. According to
some authors, there is a positive connection with HLA 39
and HLA 61 [4, 17, 18]. Due to some similarities between
SAPHO and other autoinflammatory syndromes with a
genetic basis and due to familial clustering, several other
genes are being studied. Researchers have discovered that
genes which seem to play a role in the SAPHO syndrome
are located in the chromosome 18: LPIN2 and NOD2.
LPIN2 encodes lipin 2, which is involved in modulating
apoptosis of polymorphonuclear cells, and mutations of the
NOD2 gene may lead to an abnormal immune response to
bacterial peptidoglycans via activation of the proinflam-
matory transcription factor nuclear factor kappa B [19].
There are also hypotheses of infectious disease, sug-
gesting that bone lesions are caused by a low-virulence
pathogen [2, 13]. Different types of pathogens were iso-
lated from different bone sites and pustules in the skin,
including Staphylococcus aureus [20], Haemophilus pa-
rainfluenzae, and Actinomyces, as well as Treponema
pallidum, Veillonella, and Eikenella [21]. The most
important is Propionibacterium acnes, which is identified
more often, but positive cultures can only be seen in a
small number of total bone biopsy specimens. The largest
number of P. acnes-positive biopsy specimens was proved
by Assmann and Simon [2] in their study of 21 SAPHO
patients, where 67 % of them were positive. This infectious
hypothesis is supported by increased levels of circulating
IgA in these patients and there is also evidence that intra-
articular injection of inactivated P. acnes in rats can cause
erosive joint lesions. On the other hand, according to some
of the latest considerations, since P. acnes is found in only
two-thirds of biopsies at most and the treatment with
antibiotics is effective only for as long as it is taken, it is
considered that SAPHO cannot be classified among
infections, even due to latent organisms [22–24].
There are various reports on immune system dysfunc-
tion in SAPHO [25–29]. According to some of them,
humoral immune response is hyperactive and in others, it is
hypoactive. This is similar to the cell-mediated immune
response that has been reported as normal or hyperactive;
total immune system impairment has been reported as well
[28]. Hurtado-Nedelec et al. showed that SAPHO is char-
acterized by elevated IL-8 and IL-18 levels. They had not
detect any autoantibodies among their SAPHO patients,
including rheumatoid factor, anti-CCP2, or antinuclear
antibodies. IL-8 and TNFa production by purified poly-
morphonuclear leukocytes (PMN) were elevated in these
patients compared to the controls, but the oxidative burst
and IL-18 production were normal. They also showed that,
after 28 days of etanercept therapy, PMN, IL-8, and TNFa
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production was downregulated and TNFa plasma levels
were increased [30]. Assman and Simon [2] have shown
that the proinflammatory response observed in SAPHO is
mediated by the ability of P. acnes to trigger interleukin
IL-1, IL-8, and IL-18 and TNFa release by monocytes,
keratinocytes, sebocytes, and dendritic cells.
After all, the most probable hypothesis about the etiol-
ogy of SAPHO is that it is caused by autoimmune reactions
in genetically predisposed organisms, triggered by some
infectious agent [2].
Regarding the pathogenesis of CRMO, infectious and
autoimmune theories have been suggested, but none of
them have been proven. There is a significant genetic
contribution to pathogenesis and besides LPIN2, several
other genes have to be mentioned. A susceptibility locus on
chromosome 18q21.3–18q22 affecting the proline-serine-
threonine phosphatase interacting protein 2 (PSTPIP2) has
been reported [31] in a small German CRMO cohort.
Furthermore, the disorder is also associated with poly-
morphisms of the IL-10 promoter and mutation of IL1RN
causing deficiency of the interleukin-1 receptor antagonist
(DIRA), an autosomal recessive disorder that presents with
CRMO during the neonatal period [32].
Clinical features
SAPHO syndrome should be suspected in patients who
present with osteoarticular and/or certain dermatological
clinical manifestations.
Osteoarticular manifestations involve osteitis, hyperos-
tosis, synovitis, arthropathy, and enthesopathy that present
with pain, tenderness, and sometimes swelling over the
affected areas and fever. Osteitis is the inflammation of
bone, which may involve the cortex and the medullary
cavity. Hyperostosis reflects excessive bone growth and
may result in enthesopathic new bone formation and joint
fusion (Fig. 1). Synovitis mostly manifests as nonerosive
oligoarthritis of larger joints. Joint involvement can be
primary arthritis or an extension of the osteitis adjacent to
the articular structures. Arthritis has been reported in up to
92.5 % of SAPHO cases. The axial skeleton is involved in
91 % and the peripheral joints in 36 % of cases. Besides
sternocostal and sternoclavicular joints, which are the most
commonly affected, it mainly affects the sacroiliac or hip
joints, knees, and ankles. For anterior chest wall disease,
three stages have been described (Table 1). The costocla-
vicular ligament is involved in 48 % of cases, and it is
considered a decisive early finding in SAPHO [7, 32, 33].
The smallest number of cases in the literature are based
on temporomandibular joint involvement [11, 13, 34, 35].
The percentage distribution of arthritis in various parts of
the body is demonstrated schematically in Fig. 2.
Soft tissue surrounding joints and bones can be affected
as well. It may be misinterpreted as a neoplastic or lym-
phatic mass [7, 36], and, although rare, the soft tissue
swelling can lead to serious complications, such as thoracic
outlet syndrome [11, 36–38].
Enthesopathy can lead to ligament ossification, which
can result in the development of bony bridging across
joints.
CRMO is an aseptic inflammatory disorder clinically
characterized with insidious onset of bone lesions with pain
and swelling that is often worse at night, with or without
fever. Swelling and warmth can occur over the affected
areas. It is most commonly found in the metaphyseal
regions of long bones of the lower extremities. Some other
sites, such as the clavicules, vertebral bodies, mandible,
pelvis, and small bones of the hands and feet, have been
shown to be affected as well. Involvement is multifocal,
usually unilateral, and it can be accompanied by skin
lesions (most often, palmoplantar pustulosis and psoriasis
have been described) [32, 39]. As stated earlier, some
investigators believe that CRMO is the pediatric presen-
tation of SAPHO, but it seems that the differentiating
clinical feature is mainly in the localization of inflamma-
tion: in pediatric CRMO patients, the extremities are more
often affected and in SAPHO patients, the axial skeleton
with costosternoclavicular region is the focus [5].
Fig. 1 Bilateral sternoclavicular joint edema in the SAPHO patient
Table 1 SAPHO anterior chest wall staging [26]
I. Costoclavicular ligament, may be a primary enthesopathy
II. Extension to sternoclavicular joint with sclerosis of the medial
clavicle, first rib, and adjacent sternum, and sclerotic
hypertrophy of costal cartilage
III. Osteosclerosis, hyperostosis, and bony hypertrophy of the
medial ends of the clavicles, sternum, and upper ribs, with
arthritis in the adjacent joints
J Child Orthop (2015) 9:19–27 21
123
Typical skin lesions seen in SAPHO patients include
palmoplantar pustulosis (PPP) and severe acne [40]. Acne
can manifest as acne conglobata, acne fulminans, or
hidradenitis suppurativa. Women more often develop PPP
and men show severe forms of acne. Pyoderma gangre-
nosum is the other less frequent manifestation and different
forms of psoriasis have also been described [41], as well as
Sweet’s syndrome and Sneddon–Wilkinson disease [42].
Skin lesions may vary in severity and may precede (in
50 % of the cases), follow, or occur simultaneously with
the onset of arthritis [11]. Usually, the time interval
between the onset of skin and osteoarticular manifestations
is \2 years [43], but an interval of 38 years has been
recorded in the literature [11, 44]. Sonozaki et al. [45]
showed that skin lesions precede or follow the onset of
osteoarticular lesions within 2 years in about 70 % of
patients, while Hayem et al. [11] showed that the skin
manifestations anteceded or presented at the same time as
the skeletal manifestations in 68 % of their cohort. Der-
matological manifestations are known to be resistant to
therapy and quite often have a chronic, protracted course.
Radiological features
Radiographs may show expanded bone, sclerosis and
osteolysis, periosteal reaction, or enthesopathic new bone
formation. Bone scintigraphy delineates increased uptake
in affected bone and may reveal asymptomatic disease or
abnormalities not apparent on radiographs. The advantage
of scintigraphy is the demonstration of multiple sites of
involvement, so it is helpful for the elimination of malig-
nancy or infection. Symmetric uptake in the sternoclavic-
ular region with a typical ‘‘bull‘s head’’ appearance shown
in bone scintigraphy is characteristic of the SAPHO syn-
drome (Fig. 3) [46]. It was first described by Freyschmidt
and Sternberg [47] but, even though it is considered to be
pathognomonic, it is not a very sensitive indicator of
SAPHO.
Magnetic resonance imaging (MRI) will also detect
occult lesions, may show findings not seen on plain
radiographs, and provide information about soft tissues.
Characteristic radiographic findings are hyperostosis and
osteitis. Hyperostosis is radiographically seen as diffuse
thickening of the periosteum, cortex, and endosteum, with
narrowing of the medullary canal [47]. Both are charac-
terized by increased bone sclerosis [35, 39].
In the early stages, the disease usually manifests as an
osteolytic process. As healing progresses, the lytic/sclerotic
picture is produced. Characteristic features of osteitis and
hyperostosis become more apparent with time [35].
Joint involvement is characterized by arthritis, with joint
space narrowing and, sometimes, erosions. There might be
periarticular osteopenia. Ligamentous ossifications can be
observed as well [32, 37].
Several spine lesions have been described regarding this
syndrome, and they include vertebral body corner lesions,
nonspecific spondylodiscitis and osteodestructive lesions
seen in adults and children, and osteosclerotic vertebral
lesions, paravertebral ossification, and sacroiliitis seen in
adults.
The term ‘‘corner lesion’’ describes focal cortical ero-
sion at one of the vertebral body corners, which is usually
seen in adults. Nonspecific spondylodiscitis is seen as focal














region (65 - 90 %)
Spine (32 - 52 %)
Pelvis (13 - 52 %)
Long bones (30 %)
Mandible ( 11 %)
Fig. 2 Percentage distribution of arthritis in the body (SAPHO/
CRMO)
Fig. 3 Scintigraphy findings show intensive uptake of the radiophar-
maceutical technetium-99m at the sternoclavicular joints and sternum,
which represent a ‘‘bull’s head‘‘ sign
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end plates, usually anteriorly located at the discovertebral
junction. This can be seen in up to 32 % of cases, and
single and multiple levels may be found [35]. Takigawa
et al. [14] observed nonconsecutive and consecutive mul-
tilevel lesions, both at a proportion of 38 %. It may be
painful for many weeks but, usually, with time, it becomes
asymptomatic. Rarely it is a cause of neurological com-
plications or deformity [35].
Osteodestructive lesions include osteolytic vertebral
lesions, usually limited to one vertebrae, with a variable
degree of collapse. Collapse may induce kyphosis, spinal
canal stenosis, and spinal cord injury. If it is quite marked,
it can present as a vertebra plana in children, which is not
characteristic of an adult population [14]. Sacroiliitis can
be seen and it is usually unilateral. Ankylosis may be
present as well, and it is usually connected with the relief
of pain [7, 38, 48].
Affection of the long bones is commonly seen among
children. Predominantly, the metadiaphyses are affected,
especially the distal femur, and proximal and distal tibia.
Radiographically, it may manifest as lytic lesions, sclerotic
or mixed lesions, and periosteal reaction may eventually
develop. MRI is the technique of choice in young patients
suspected of SAPHO/CRMO, particularly due to the lack
of radiation requirements and its sensitivity in detecting
early subclinical lesions. It is seen as bone marrow edema,
which shows up as hypointense on T1 and hyperintense on
T2 signals in the affected metaphysis. As the disease pro-
gresses, hypointense T1 and T2 signals in the medullary
space and cortex represent medullary sclerosis and cortical
thickening [17]. Lesions are usually multiple and often
symmetrical. Involvement of the adjacent epiphysis and
altered bone growth are rare [17, 35].
Many of the radiological manifestations of the disease
can be seen on plain radiographs. It is important to
emphasize that radiographs made during the first 3 months
of the disease course are normal in 80 % of cases and all
patients had abnormal radiographs at the end of follow-up
[38]. Similar findings were shown by Fritz et al. [49]. They
found that the sensitivity of conventional radiography in
the early stages of the disease is 13 % and, compared to
MRI, it shows only 16 % of the lesions seen on MRI. For
identifying subclinical foci, whole-body scintigraphy or
whole-body MRI is very useful. Actually, if initial radio-
graphs are negative and disease is suspected, bone scin-
tigraphy is used as the next step to detect occult
inflammatory lesions and clinically suspected localizations.
Because of increased cost, the use of whole-body MRI is
recommended for indeterminate cases, monitoring of dis-
ease activity, and for better delineation of soft tissue
changes. Intravenous contrast will highlight abscesses and
other soft tissue changes that may be associated with more
aggressive conditions [17]. It should be kept in mind that
imaging procedures cannot accurately distinguish among
SAPHO/CRMO, malignancy, and osteomyelitis, and such
findings should always be interpreted within other clinical
and laboratory parameters.
Laboratory tests
There are no laboratory tests that are diagnostic of SAPHO.
They can be normal or may show elevated inflammatory
markers, such as erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), and elevated levels of compo-
nents of complements C3 and C4. Mild leukocytosis and
mild anemia were observed as well. Compared to healthy
controls, these patients have elevated levels of immuno-
globulin A [2, 50]. A study searching for some specific
antibody profiles for those patients has been conducted
recently, but, unfortunately, without any success. Hurtado-
Nedelec et al. [30] showed significantly increased levels of
IgA in their cohort of 29 SAPHO patients, while the levels
of IgM and IgG were normal. This information can pos-
sibly be used as an additional tool in making the diagnosis,
but further investigations need to be done. Also, some
studies exhibit correlation with B39 and B61 [18].
Histopathological findings
Osteitis refers to bone inflammation and appears histopa-
thologically as sterile inflammatory infiltrate [3]. Early
during the disease course, the predominant finding is PMN
infiltrate. In the intermediate stage, the infiltrate is com-
posed primarily of mononuclear cells and in the late stage,
bone trabeculae are enlarged and sclerotic, with an
increased number of osteocytes and marrow fibrosis. Skin
biopsy of the affected skin shows neutrophilic pseudo-
abscesses [30]. SAPHO and CRMO lesions are histologi-
cally identical [40].
Diagnostic criteria
There are several published diagnostic criteria for SAPHO
and the presence of only one of the inclusion criteria is
sufficient for making the diagnosis. The criteria suggested
by Kahn and the other by Benhamou are the most fre-
quently mentioned. All of them are preliminary and need
further validation (please see Tables 2, 3, and 4). With
regard to all of them, it can be said that the criteria made by
Kahn and modified in 2003 seems to be the most precise.
Even though the existence of such criteria is very helpful in
making the diagnosis, it is very doubtful as to whether bone
and joint involvement associated with chronic bowel
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diseases (which is one of the inclusion criteria) can be
classified as SAPHO syndrome, since arthropathies asso-
ciated with inflammatory bowel disease are included in the
EULAR/ILAR criteria for juvenile idiopathic arthritis
(JIA) [51, 52].
Furthermore, it should be discussed whether CRMO is
the pediatric presentation of SAPHO or an entity by itself.
For those reasons, these criteria need further modifications.
Diagnosis and differential diagnosis
The diagnosis is usually made by a rheumatologist, who
will consult with a dermatologist to treat the skin compo-
nent of the disease. Making a diagnosis is challenging
because not all symptoms are always apparent or present at
the same time, or some may be subtle. In making the
diagnosis, the above-mentioned clinical, radiological, and
laboratory characteristics, as well as diagnostic criteria, are
used. Regarding differential diagnosis, early during the
disease course, infectious (osteomyelitis) and neoplastic
etiology must be excluded. Tumors with local extension
should be considered—thyroid cancer, lymphoma or oste-
osarcoma, metastatic breast, prostate cancer, and neuro-
blastoma [17]. Psoriatic arthritis with axial skeleton
manifestation and pustular psoriasis, a special subgroup of
psoriatic disease, can be the cause of diagnostic dilemma.
Radiographic signs of osteitis with hyperostosis are not
often seen in psoriatic arthritis [53]. Furthermore, differ-
ential diagnosis includes Paget’s disease (genetic disease
with increased bone turnover, repeated fractures and
deformities, markedly elevated level of alkaline phospha-
tase, and radiographs revealing characteristic mosaic pat-
tern, both osteolysis and osteosclerosis) and Sweet’s
syndrome (neutrophilic dermatosis with elevated inflam-
matory markers that can be accompanied with aching
joints). When the clavicle is affected, Tietze’s syndrome
(swelling of the costal cartilages, mostly in adults, rare in
children) and avascular necrosis of the clavicular epiphysis
are considered as well. Regarding differential diagnosis in
the pediatric age group, it also includes Ewing’s sarcoma,
histiocytosis, Majeed syndrome, or DIRA. Majeed syn-
drome is an autosomal recessive (AR) disorder that pre-
sents with early-onset CRMO and dyserythropoietic
anemia. DIRA is an AR disorder that manifests with
CRMO in the neonatal period with generalized pustulosis,
osteitis, periostitis, and systemic inflammation [17, 32, 54].
Differential diagnosis of SAPHO and CRMO is shown in
Table 5.
Finally, it should always be kept in mind that SAPHO
and CRMO are diagnosed by exclusion. When only one
site is involved in the absence of skin lesions, making the
diagnosis can be difficult and biopsy may be needed.
Sterile osteitis (little or no medullary change) is one of the
major characteristics of this syndrome, but the diagnosis
Table 2 Diagnostic criteria proposed by Kahn for SAPHO syndrome
diagnosis, 1994 [41]
1. Chronic recurrent multifocal sterile and axial osteomyelitis,
with or without dermatosis
2. Acute, subacute, or chronic arthritis associated with
palmoplantar pustulosis, pustulous psoriasis, or severe acne
3. Any sterile osteitis associated with palmoplantar pustulosis,
pustulous psoriasis, or severe acne
Table 3 Diagnostic criteria proposed by Kahn for SAPHO syndrome
diagnosis, modified in 2003 (from Kahn; American College of
Rheumatology 67th Annual Scientific Meeting, October 2003) [6]
Inclusion
Bone–joint involvement associated with PPP and psoriasis
vulgaris
Bone–joint involvement associated with severe acne
Isolated sterilea hyperostosis/osteitis (adults)
Chronic recurrent multifocal osteomyelitis (children)
Bone–joint involvement associated with chronic bowel diseases
Exclusion
Infectious osteitis
Tumoral conditions of the bone
Noninflammatory condensing lesions of the bone
a Exception: growth of Propionibacterium acnes
Table 4 Diagnostic criteria proposed by Benhamou for SAPHO
syndrome diagnosis [29]
1. Osteoarticular manifestations in severe acne
2. Osteoarticular manifestations in palmoplantar pustulosis
3. Hyperostosis with or without dermatosis and
4. Recurrent multifocal chronic osteomyelitis involving the axial
or peripheral skeleton, with or without dermatosis
Table 5 Differential diagnosis
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can never be done by histological results alone, and the
advantage of biopsy is just to exclude other diagnoses [24,
46].
Treatment
Because to the variety of clinical presentations, the treat-
ment of SAPHO syndrome remains a challenge and out-
comes are known to be disappointing, especially with the
skin component of the disease. There have been no ran-
domized controlled trials on the effectiveness of various
therapies, but nonsteroidal anti-inflammatory drugs
(NSAIDs) are generally considered as the first-line treat-
ment option [4]. Antimicrobial therapy is useful in patients
with positive biopsy cultures, but it has little or no effect in
others. Successful treatment has been reported for doxy-
cycline, azithromycin, sulfamethoxazole/trimethoprim, and
clindamycin [20, 55]. Azithromycin acts not only as an
antimicrobial, but also as an anti-inflammatory and
immunomodulatory drug, and Schilling and Wagner sug-
gest the simultaneous usage of azithromycin together with
calcitonin (osteotropic drug) [56]. Other treatment options
include colchicine, corticosteroids, bisphosphonates, and
disease-modifying agents, such as methotrexate, sulfasal-
azine, and anti-TNFa therapy. Bisphosphonates act by
inhibiting bone resorption and turnover, and by possible
anti-inflammatory activity that suppresses the production
of IL-1, IL-6, and TNFa [57]. They have no effect on skin
lesions. Local corticosteroid injections have also been
tried, but this treatment modality has a significant effect
only on osteitis lesions [53]. Some authors used cortico-
steroids orally and, in that case, they will act on both
skeletal and skin manifestations. Dermatologists use topi-
cal corticosteroids, psoralen plus ultraviolet A (PUVA)
photochemotherapy, and retinoids [58]. Disease-modifying
agents are only indicated when symptoms persist for at
least 4 weeks, despite adequate NSAID therapy. There is
increasing evidence of anti-TNFa usage in the treatment of
such patients. Case reports and case series on TNFa
blockade often demonstrate a marked improvement in the
clinical picture, regardless of whether or not this treatment
is permanently effective. The most often published cases in
the literature are about the use of infliximab in these
patients. Usually, 5 mg/kg at weeks 0, 2, and 6 followed by
a 6–8-week interval has been used, just like that used in
spondyloarthropathies. Lower doses of infliximab and
reduction in the duration of intervals have been tested, but
it has been noted that decreased infusion intervals like in
spondyloarthropathies and lower dosages cannot maintain
the remission of disease [58]. Both skeletal and cutaneous
lesions responded well in most of the described cases, with
exception of PPP, which sometimes failed to respond. In
some cases, infliximab induced exacerbation of skin man-
ifestation. Arias-Santiago et al. [59] suggested adalimumab
as a possible alternative therapy in such cases, and there are
also reports on the successful treatment of SAPHO with
etanercept and the IL-1 receptor antagonist anakinra.
Anakinra appeared to be helpful in five out of six SAPHO
patients, two of which previously failed to respond to TNF
blockers [60]. Autologous bone transplantation using
microvascular flaps is applied as an experimental treatment
procedure [15].
Physiotherapy can always be used as an additional
treatment for osteoarticular manifestations. Surgery is
considered for patients whose condition has failed to
respond to all other therapeutic interventions [61]. Wide
resections are reserved to treat complications when patients
develop deformity or loss of function with pain [15]. There
are several reports in the literature about the surgical
treatment of such patients; for example, resection of the
medial clavicle or the sternoclavicular joint, which seemed
to provide variable improvement in pain, although some
authors report no improvement with this intervention [54].
Furthermore, mandibular involvement has been treated
with minor surgical procedures, such as decortications and
curettage, but extensive extirpation of the cortical jaw was
done as well [62].
Clinical course and conclusion
Except for a minority of patients who have a self-limited
course, most of them have either relapsing–remitting
course or chronic indolent pattern. Over the long term,
rheumatic manifestations in most patients show little pro-
gression [11]. Maugars et al. [38] revealed that, after an
average follow-up of around 12 years, 53 % of patients
develop disease at new sites.
Colina et al. [48] identified that female sex, anterior
chest wall involvement, peripheral arthritis, skin lesions,
and high inflammatory parameters at first presentation are
related to the chronic course of the disease.
SAPHO is rare, but as awareness increases, it is being
reported more often. It should be suspected when evalu-
ating patients with lytic, sclerotic, or hyperostotic bone
lesions and pain.
This paper is an attempt to increase awareness about
SAPHO syndrome among orthopedic pediatric surgeons
and prompt recognition will help avoid unnecessary
examinations, biopsies, surgical treatments, antibiotic
therapy, or possible physical and psychological impair-
ments associated with the disease, especially among chil-
dren. It is important to remember that the skin
manifestations and bony involvement may not be present at
the same time, and it would be best to refer suspected
J Child Orthop (2015) 9:19–27 25
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SAPHO patients to the rheumatologist/dermatologist. Fur-
ther examination and randomized controlled trials need to
be done in order to better understand the disease, as well as
to aid the development and establishment of adequate
therapies.
Conflict of interest The author declares that there were no conflicts
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Kerrison C, Davidson JE, Cleary AG, Beresford MW (2004)
Pamidronate in the treatment of childhood SAPHO syndrome.
Rheumatology (Oxford) 43:1246–1251
2. Assmann G, Simon P (2011) The SAPHO syndrome—are
microbes involved? Best Pract Res Clin Rheumatol 25:423–434
3. Matzaroglou Ch, Velissaris D, Karageorgos A, Marangos M,
Panagiotopoulos E, Karanikolas M (2009) SAPHO syndrome
diagnosis and treatment: report of five cases and review of the
literature. Open Orthop J 3:100–106
4. Khanna L, El-Khoury GY (2012) SAPHO syndrome—a pictorial
assay. Iowa Orthop J 32:189–195
5. Rohekar G, Inman RD (2006) Conundrums in nosology: syno-
vitis, acne, pustulosis, hyperostosis, and osteitis syndrome and
spondylarthritis. Arthritis Rheum 55:665–669
6. Hayem G (2004) SAPHO syndrome. Rev Prat 54:1635–1636
7. Earwaker JWS, Cotten A (2003) SAPHO: syndrome or concept?
Imaging findings. Skeletal Radiol 32:311–327
8. Tyrrell PN, Cassar-Pullicino VN, Eisenstein SM, Monach JF,
Darby AJ, McCall IW (1996) Back pain in childhood. Ann
Rheum Dis 55:789–793
9. Wallach D (2000) Neutrophilic dermatoses: an overview. Clin
Dermatol 18:229–231
10. Van Doornum S, Barraclough D, McColl G, Wicks I (2000)
SAPHO: rare or just not recognized? Semin Arthritis Rheum
30:70–77
11. Hayem G, Bouchaud-Chabot A, Benali K et al (1999) SAPHO
syndrome: a long-term follow-up study of 120 cases. Semin
Arthritis Rheum 29:159–171
12. Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA,
Brogan PA (2010) Biologic therapy in refractory chronic non-
bacterial osteomyelitis of childhood. Rheumatology (Oxford)
49:1505–1512
13. McPhillips A, Wolford LM, Rodrigues DB (2010) SAPHO syn-
drome with TMJ involvement: review of the literature and case
presentation. Int J Oral Maxillofac Surg 39:1160–1167
14. Takigawa T, Tanaka M, Nakanishi K et al (2008) SAPHO syn-
drome associated spondylitis. Eur Spine J 17:1391–1397
15. Mochizuki Y, Omura K, Hirai H, Kugimoto T, Osako T, Taguchi
T (2012) Chronic mandibular osteomyelitis with suspected
underlying synovitis, acne, pustulosis, hyperostosis, and osteitis
(SAPHO) syndrome: a case report. J Inflamm Res 5:29–35
16. Hukuda S, Minami M, Saito T et al (2001) Spondyloarthropa-
thies in Japan: nationwide questionnaire survey performed by
the Japan Ankylosing Spondylitis Society. J Rheumatol
28:554–559
17. Thakur U, Blacksin M, Beebe K, Neilson JC, Dashefsky B,
Tagoylo G (2012) Synovitis, acne, pustulosis, hyperostosis and
osteitis (SAPHO) and chronic recurrent multifocal osteomyelitis
(CRMO): role of imaging in diagnosis. Radiography 18:221–224
18. De Souza A, Solomon GE, Strober BE (2011) SAPHO syndrome
associated with hidradenitis suppurativa successfully treated with
infliximab and methotrexate. Bull NYU Hosp Jt Dis 69:185–187
19. Burgemeister LT, Baeten DL, Tas SW (2012) Biologics for rare
inflammatory diseases: TNF blockade in the SAPHO syndrome.
Neth J Med 70:444–449
20. Rozin AP, Nahir AM (2007) Is SAPHO syndrome a target for
antibiotic therapy? Clin Rheumatol 26:817–820
21. Arnson Y, Rubinow A, Amital H (2008) Secondary syphilis
presenting as SAPHO syndrome features. Clin Exp Rheumatol
26:1119–1121
22. Trimble BS, Evers CJ, Ballaron SA, Young JM (1987) Intraar-
ticular injection of Propionibacterium acnes causes an erosive
arthritis in rats. Agents Actions 21:281–283
23. Assmann G, Kueck O, Kirchhoff T et al (2009) Efficacy of
antibiotic therapy for SAPHO syndrome is lost after its discon-
tinuation: an interventional study. Arthritis Res Ther 11:R140
24. Berthelot JM, de la Cochetie`re MF, Potel G, Le Goff B, Maugars
Y (2013) Evidence supporting a role for dormant bacteria in the
pathogenesis of spondylarthritis. Joint Bone Spine 80:135–140
25. Ferguson PJ, Lokuta MA, El-Shanti HI, Muhle L, Bing X,
Huttenlocher A (2008) Neutrophil dysfunction in a family with
a SAPHO syndrome-like phenotype. Arthritis Rheum
58:3264–3269
26. Eyrich GK, Langenegger T, Bruder E, Sailer HF, Michel BA
(2000) Diffuse chronic sclerosing osteomyelitis and the synovitis,
acne, pustolosis, hyperostosis, osteitis (SAPHO) syndrome in two
sisters. Int J Oral Maxillofac Surg 29:49–53
27. Grosjean C, Hurtado-Nedelec M, Nicaise-Roland P et al (2010)
Prevalence of autoantibodies in SAPHO syndrome: a single-
center study of 90 patients. J Rheumatol 37:639–643
28. Malmstro¨m M, Fyhrquist F, Kosunen TU, Tasanen A (1983)
Immunological features of patients with chronic sclerosing
osteomyelitis of the mandible. Int J Oral Surg 12:6–13
29. Montonen M, Lindqvist C (2003) Diagnosis and treatment of
diffuse sclerosing osteomyelitis of the jaws. Oral Maxillofac Surg
Clin North Am 15:69–78
30. Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P et al
(2008) Characterization of the immune response in the synovitis,
acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.
Rheumatology (Oxford) 47:1160–1167
31. Golla A, Jansson A, Ramser J et al (2002) Chronic recurrent
multifocal osteomyelitis (CRMO): evidence for a susceptibility
gene located on chromosome 18q21.3–18q22. Eur J Hum Genet
10:217–221
32. Ferguson PJ, Sandu M (2012) Current understanding of the
pathogenesis and management of chronic recurrent multifocal
osteomyelitis. Curr Rheumatol Rep 14:130–141
33. Dihlmann W, Dihlmann SW (1991) Acquired hyperostosis syn-
drome: spectrum of manifestations at the sternocostoclavicular
region. Radiologic evaluation of 34 cases. Clin Rheumatol
10:250–263
34. Girschick HJ, Krauspe R, Tschammler A, Huppertz HI (1998)
Chronic recurrent osteomyelitis with clavicular involvement in
children: diagnostic value of different imaging techniques and
therapy with non-steroidal anti-inflammatory drugs. Eur J Pediatr
157:28–33
35. Depasquale R, Kumar N, Lalam RK et al (2012) SAPHO: what
radiologists should know. Clin Radiol 67:195–206
36. Kahn MF, Hayem F, Hayem G, Grossin M (1994) Is diffuse
Sclerosing osteomyelitis of the mandible part of the synovitis,
acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome?
Analysis of seven cases. Oral Surg Oral Med Oral Pathol
78:594–598
26 J Child Orthop (2015) 9:19–27
123
37. van Holsbeeck M, Martel W, Dequeker J et al (1989) Soft tissue
involvement, mediastinal pseudotumor, and venous thrombosis in
pustulotic arthro-osteitis. A study of eight new cases. Skeletal
Radiol 18:1–8
38. Maugars Y, Berthelot JM, Ducloux JM, Prost A (1995) SAPHO
syndrome: a followup study of 19 cases with special emphasis on
enthesis involvement. J Rheumatol 22:2135–2141
39. Cotten A, Flipo RM, Mentre A, Delaporte E, Duquesnoy B, Chas-
tanet P (1995) SAPHO syndrome. Radiographics 15:1147–1154
40. Monsour PAJ, Dalton JB (2010) Chronic recurrent multifocal
osteomyelitis involving the mandible: case reports and review of
the literature. Dentomaxillofac Radiol 39:184–190
41. Kahn MF, Khan MA (1994) The SAPHO syndrome. Baillieres
Clin Rheumatol 8:333–362
42. Govoni M, Colina M, Massara A, Trotta F (2009) SAPHO syn-
drome and infections. Autoimmun Rev 8:256–259
43. Fruehauf J, Cierny-Modre` B, Caelen Lel-S, Schwarz T, Weinke
R, Aberer E (2009) Response to infliximab in SAPHO syndrome.
BMJ Case Rep. doi:10.1136/bcr.10.2008.1145
44. Sugimoto H, Tamura K, Fujii T (1998) The SAPHO syndrome:
defining the radiologic spectrum of diseases comprising the
syndrome. Eur Radiol 8:800–806
45. Sonozaki H, Mitsui H, Miyanaga Y et al (1981) Clinical features
of 53 cases with pustulotic arthro-osteitis. Ann Rheum Dis
40:547–553
46. Quirico Rodrı´guez M, Casa´ns Tormo I, Redal Pen˜a MC, Lo´pez
Castillo V (2010) The importance of bone scintigraphy in the
diagnosis of sapho syndrome. Rev Esp Med Nucl 29:127–130
47. Freyschmidt J, Sternberg A (1998) The bullhead sign: scinti-
graphic pattern of sternocostoclavicular hyperostosis and pu-
stulotic arthroosteitis. Eur Radiol 8:807–812
48. Colina M, Govoni M, Orzincolo C, Trotta F (2009) Clinical and
radiologic evolution of synovitis, acne, pustulosis, hyperostosis,
and osteitis syndrome: a single center study of a cohort of 71
subjects. Arthritis Rheum 61:813–821
49. Fritz J, Tzaribatchev N, Claussen CD, Carrino JA, Horger MS
(2009) Chronic recurrent multifocal osteomyelitis: comparison of
whole-body MR imaging with radiography and correlation with
clinical and laboratory data. Radiology 252:842–851
50. Toussirot E, Dupond JL, Wendling D (1997) Spondylodiscitis in
SAPHO syndrome. A series of eight cases. Ann Rheum Dis
56:52–58
51. Cassidy JT, Levinson JE, Bass JC et al (1986) A study of clas-
sification criteria for a diagnosis of juvenile rheumatoid arthritis.
Arthritis Rheum 29:274–281
52. Petty RE, Southwood TR, Baum J et al (1998) Revision of the
proposed classification criteria for juvenile idiopathic arthritis:
Durban, 1997. J Rheumatol 25:1991–1994
53. Jung J, Molinger M, Kohn D, Schreiber M, Pfreundschuh M,
Assmann G (2012) Intra-articular glucocorticosteroid injection
into sternocostoclavicular joints in patients with SAPHO syn-
drome. Semin Arthritis Rheum 42:266–270
54. Carroll MB (2011) Sternocostoclavicular hyperostosis: a review.
Ther Adv Musculoskelet Dis 3:101–110
55. Wagner AD, Andresen J, Huelsemann J, Zeidler H (1997) Long-
term antibiotic therapy successful in patients with SAPHO syn-
drome. Arthritis Rheum 40:S62
56. Schilling F, Wagner AD (2000) Azithromycin: an anti-inflam-
matory effect in chronic recurrent multifocal osteomyelitis? A
preliminary report. Z Rheumatol 59:352–353
57. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004)
SAPHO syndrome treated with pamidronate: an open-label study
of 10 patients. Rheumatology (Oxford) 43:658–661
58. Greenspan A, Gerscovich E, Szabo RM, Matthews JG 2nd (1991)
Condensing osteitis of the clavicle: a rare but frequently mis-
diagnosed condition. AJR Am J Roentgenol 156:1011–1015
59. Arias-Santiago S, Sanchez-Cano D, Callejas-Rubio JL, Ferna´n-
dez-Pugnaire MA, Ortego-Centeno N (2010) Adalimumab treat-
ment for SAPHO syndrome. Acta Derm Venereol 90:301–302
60. Wendling D, Prati C, Aubin F (2012) Anakinra treatment of
SAPHO syndrome: short-term results of an open study. Ann
Rheum Dis 71:1098–1100
61. Taylor HG, Dawes PT (1992) Sterno-costo-clavicular hyperos-
tosis. Br J Clin Pract 46(4):276–278
62. Wannfors K (2013) SAPHO (synovitis–acne–pustulosis–hyper-
ostosis–oste itis): a multidisciplinary approach. Oral Surg Oral
Med Oral Pathol Oral Radiol 116:692–697
J Child Orthop (2015) 9:19–27 27
123
